A bicentre, randomized, prospective open-label study aimed at defining a DNAaemia versus antigenaemia cutoff for guiding preemptive therapy of human cytomegalovirus (HCMV) infections in solid organ transplant recipients (SOTR) was completed. Overall, 99 patients were enrolled in the DNAaemia arm and 101 patients in the antigenaemia arm. Patients were randomized to be monitored for HCMV infection in the blood by either assay. Antiviral treatment was started in both seropositive and seronegative patients when levels greater than 300,000 DNA copies/ml blood or 100 pp65-positive leukocytes in the relevant arm were reached.
Results
HCMV infection was detected in 81/99 (81.8%) patients in the DNAaemia arm and in 87/101 (86.1%) patients in the antigenaemia arm (P=ns). Antiviral treatment was given to 23/99 (23.0%) patients in the DNAaemia arm and 42/101 (41.0%) patients in the antigenaemia arm (P=0.01). In the DNAaemia arm, antiviral therapy was significantly delayed and duration of the first course of treatment was significantly greater than in the antigenaemia arm. However, total duration of treatment was comparable in the two arms. No case of HCMV disease occurred in patients treated after reaching the relevant cutoff. However, four patients (three in the antigenaemia arm, and one in the DNAaemia arm) suffered from HCMV disease prior to reaching the relevant cutoff.
Conclusions
Compared with antigenaemia, a single DNAaemia cutoff: (i) significantly reduces the number of patients requiring treatment; (ii) may be safely adopted to guide preemptive therapy of both primary and reactivated HCMV infections in SOTR; and (iii) does not significantly modify the overall duration of treatment.
References
1.
KusneS., ShapiroR., FungJ.Prevention and treatment of cytomegalovirus infection in organ transplant recipients.Transplant Infect Dis1999; 1: 187–203.
2.
RubinR.H.Prevention and treatment of cytomegalovirus disease in heart transplant recipients.J Heart Lung Transplant2000; 19: 731–735.
3.
MeriganT.C., RenlundD.G., KeayS.A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation.New Engl J Med1992; 326: 1182–1186.
4.
KellyJ.L., AlbertR.K., WoodD.E., RaghuG.Effect of a 6-week prophylactic ganciclovir regimen and the role of serial cytomegalovirus antibody testing in lung transplant recipients.Transplantation1995; 59: 1144–1147.
5.
RubinR.H.Preemptive therapy in immunocompromised hosts.New Engl J Med1991; 324: 1057–1059.
6.
GrossiP., MinoliL., PercivalleE., IrishW., ViganòM., GernaG.Clinical and virological monitoring of human cytomegalovirus infection in 294 heart transplant recipients.Transplantation1995; 59: 847–851.
7.
BoeckhM., GooleyT.A., MyersonD., CunninghamT., SchochG., BowdenR.A.Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomised double-blind study.Blood1996; 88: 4063–4071.
8.
EganJ.J., LomaxJ., BarberL.Preemptive treatment for the prevention of cytomegalovirus disease in lung and heart transplant recipients.Transplantation1998; 65: 747–752.
9.
Van der BijW., SchirmJ., TorensmaR., van SonW.J., TegzessA.M., TheT.H.Comparison between viremia and antigenemia for detection of cytomegalovirus in blood.J Clin Microbiol1988; 26: 2531–2535.
10.
RevelloM.G., PercivalleE., ZavattoniM., PareaM., GrossiP., GernaG.Detection of human cytomegalovirus immediate early antigen in leukocytes as a marker of viremia in immunocompromised patients.J Med Virol1989; 29: 88–93.
11.
GernaG., RevelloM.G., PercivalleE., MoriniF.Comparison of different immunostaining techniques and monoclonal antibodies to the lower matrix phosphoprotein (pp65) for optimal quantitation of human cytomegalovirus antigenemia.J Clin Microbiol1992; 30: 1232–1237.
12.
RevelloM.G., PercivalleE., Di MatteoA., MoriniF., GernaG.Nuclear expression of the lower matrix protein of human cytomegalovirus in peripheral blood leukocytes of immunocompromised viraemic patients.J Gen Virol1992; 73: 437–442.
13.
GrefteJ.M.N., van der GunB.T.F., SchmolkeS.The lower matrix protein pp65 is the principal viral antigen present in peripheral blood leukocytes during an active cytomegalovirus infection.J Gen Virol1992; 73: 2923–2932.
14.
GernaG., BaldantiF., MiddeldorpJ.M.Clinical significance of expression of human cytomegalovirus pp67 late transcript in heart, lung, and bone marrow transplant recipients as determined by nucleic acid sequence-based amplification.J Clin Microbiol1999; 37: 902–911.
15.
GernaG., BaldantiF., LilleriD.Human cytomegalovirus pp67 mRNAemia versus pp65 antigenemia for guiding preemptive therapy in heart and lung transplant recipients: a prospective, randomised, controlled, open-label trial.Transplantation2003; 75: 1012–1019.
16.
GernaG., ZavattoniM., BaldantiF.Human cytomegalovirus (HCMV) leukoDNAemia correlates more closely with clinical symptoms than antigenemia and viremia in heart and heart-lung transplant recipients with primary HCMV infection.Transplantation1998; 65: 1378–1385.
17.
GernaG., LilleriD., FornaraC.Monitoring of human cytomegalovirus-specific CD4+ and CD8+ T-cell immunity in patients receiving solid organ transplantation.Am J Transplant2006; 6: 2356–2364.
18.
GernaG., ZavattoniM., PercivalleE., GrossiP., TorselliniM., RevelloM.G.Rising levels of human cytomegalovirus (HCMV) antigenemia during initial antiviral treatment of solid-organ transplant recipients with primary HCMV infection.J Clin Microbiol1998; 36: 1113–1116.
19.
EinseleH., EhningerG., HebartH.Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation.Blood1995; 86: 2815–2820.
20.
MattesF.M., HainsworthE.G., GerettiA-MA randomised controlled trial comparing ganciclovir to ganciclovir plus foscarnet (each at half dose) for preemptive therapy of cytomegalovirus infection in transplant recipients.J Infect Dis2004; 189: 1355–1361.
21.
PayaC.V., WilsonJ.A., EspyM.J.Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: a randomised, placebo-controlled trial.J Infect Dis2002; 185: 854–860.
22.
GernaG., FurioneM., BaldantiF., SarasiniA.Comparative quantitation of human cytomegalovirus DNA in blood leukocytes and plasma of transplant and AIDS patients.J Clin Microbiol1994; 32: 2709–2717.
23.
FoxJ.C., GriffithsP.D., EmeryV.C.Quantification of human cytomegalovirus DNA using the polymerase chain reaction.J Gen Virol1992; 73: 2405–2408.
24.
BoivinG., OlsonC.A., QuirkM.R., St-CyrS.M., JordamM.C.Quantitation of human cytomegalovirus glycoprotein H in cells using competitive PCR and a rapid fluorescence-based detection system.J Virol Methods1995; 51: 329–342.
25.
HiguchiR., FocklerC., DollingerC., WatsonR.Kinetic PCR analysis: real-time monitoring of DNA amplification reactions.Biotechnology (NY)1993; 11: 1926–1030.
26.
LilleriD., BaldantiF., GattiM.Clinically-based determination of safe DNAemia cutoff levels for preemptive therapy of human cytomegalovirus infections in solid organ and hematopoietic stem cell transplant recipients.J Med Virol2004; 73: 412–418.
27.
RazonableR.R., BrownR.A., WilsonJ.The clinical use of various blood compartments for cytomegalovirus (CMV) DNA quantitation in transplant recipients with CMV disease.Transplantation2002; 73: 968–973.
28.
GernaG., LilleriD.Monitoring transplant patients for human cytomegalovirus: diagnostic update.Herpes2006; 13: 4–11.
29.
GernaG., PercivalleE., BaldantiF.Human cytomegalovirus replicates abortively in polymorphonuclear leukocytes after transfer from infected endothelial cells via transient microfusion events.J Virol2000; 74: 5629–5638.
30.
GrossiP., KusneS., RinaldoC.Guidance of ganciclovir therapy with pp65 antigenemia in cytomegalovirus-free recipients of livers from seropositive donors.Transplantation1996; 61: 1659–1660.
31.
GernaG., LilleriD., ZeccaM.Rising antigenemia levels may be misleading in preemptive therapy of human cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients.Haematologica2005; 90: 526–533.
32.
GernaG., SarasiniA., LilleriD.In vitro model for the study of the dissociation of increasing antigenemia and decreasing DNAemia and viremia during treatment of human cytomegalovirus infection with ganciclovir in transplant recipients.J Infect Dis2003; 188: 1639–1647.
33.
RevelloM.G., ZavattoniM., SarasiniA., PercivalleE., SimonciniL., GernaG.Human cytomegalovirus in blood of immunocompetent persons during primary infection: prognostic implications for pregnancy.J Infect Dis1998; 177: 1170–1175.
34.
LjungmanP., GriffithsP., PayaC.Definitions of HCMV infection and disease in transplant recipients.Clinical Infect Dis2002; 34: 1094–1097.
35.
GernaG., RevelloM.G., PercivalleE., TorselliniM.A 6-hour micreoneutralization assay for human cytomegalovirus antibody by using monoclonal antibodies.Serodiagnosis & Immunotherapy of Infectious Diseases1990; 4: 243–247.
36.
GernaG., VituloP., RovidaF.Impact of human metapneumovirus and human cytomegalovirus versus other respiratory viruses on the lower respiratory tract infections of lung transplant recipients.J Med Virol2006; 78: 408–416.
37.
BoomR., SolC.J.A., SalimansM.M.M., JansenC.L., Wertheimvan DillenP.M.E., van der NordaaJ.Rapid and simple method for purification of nucleic acids.J Clin Microbiol1990; 28: 495–503.
38.
GernaG., PercivalleE., RevelloM.G., MoriniF.Correlation of quantitative human cytomegalovirus pp65-, p72-, and p150-antigenemia, viremia and circulating endothelial giant cells with clinical symptoms and antiviral treatment in immunocompromised patients.Clin Diagn Virol1993; 1: 47–59.
39.
GernaG., PercivalleE., TorselliniM., RevelloM.G.Standardization of the human cytomegalovirus antigenemia assay by means of in vitro generated pp65-positive peripheral blood polymorphonuclear leukocytes.J Clin Microbiol1998; 36: 3585–3589.
40.
GernaG., RevelloM.G., PercivalleE., ZavattoniM., PareaM., BattagliaM.Quantification of human cytomegalovirus viremia by using monoclonal antibodies to different viral proteins.J Clin Microbiol1990; 28: 2681–2688.
41.
LozzaL., LilleriD., PercivalleE.Simultaneous quantification of human cytomegalovirus (HCMV)-specific CD4+ and CD8+ T cells by a novel method using monocyte-derived HCMV-infected immature dendritic cells.Eur J Immunol2005; 35: 1795–1804.
42.
GernaG., PercivalleE., LilleriD.Dendritic cell infection by human cytomegalovirus is restricted to strains carrying functional UL 131–128 genes and mediates efficient viral antigen presentation to CD8+ T cells.J Gen Virol2005; 86: 275–284.
43.
ParenteF., Bianchi PorroG. and the Italian Cytomegalovirus Study Group. Treatment of cytomegalovirus esophagitis in patients with acquired immune deficiency syndrome: a randomised controlled study of foscarnet versus ganciclovir.Am J Gastroenterol1998; 93: 317–322.
44.
SanchezJ.L., KrugerR.M., ParanjothiS.Relationship of cytomegalovirus viral load in blood to pneumonitis in lung transplant recipients.Transplantation2001; 72: 733–735.
45.
WestallG.P., MichaelidisA., WilliamsT.J., SnellJ.I., KotsimbosT.C.Human cytomegalovirus load in plasma and bronchoalveolar lavage fluid: a longitudinal study of lung transplant recipients.J Infect Dis2004; 190: 1076–1083.
46.
KalpoeJ.S., KroesA.C., de JongM.D.Validation of clinical application of cytomegalovirus plasma DNA load measurement and definition of treatment criteria by analysis of correlation to antigen detection.J Clin Microbiol2004; 42: 1498–1504.
47.
MengelleC., PasquierC., RostaingL.Quantitation of human cytomegalovirus in recipients of solid organ transplants by real-time quantitative PCR and pp65 antigenemia.J Med Virol2003; 69: 225–231.
48.
LiH., DummerJ.S., EstesW.R., MengS., WrightP.F., TangY.W.Measurements of human cytomegalovirus loads by quantitative real-time PCR for monitoring clinical intervention in transplant recipients.J Clin Microbiol2003; 41: 187–191.
49.
Martin-DávilaP., FortúnJ., GutiérrezC.Analysis of a quantitative PCR assay for CMV infection in liver transplant recipients: an intent to find the optimal cut-off value.J Clin Virol2005; 33: 138–144.
